Report: Emergent pauses J&J vaccine production at Baltimore plant

According to a published report by Reuters, the production of Johnson & Johnson's Covid-19 vaccine at a US manufacturing plant was stopped by the FDA, as the agency looks into an error that caused in millions of doses to be contaminated last month.

Emergent BioSolutions Inc, the organization that owns and runs the Baltimore plant that had been making vaccine for J&J, stated in a regulatory filing that on April 16, FDA requested a pause in production of new drug substance for the shot pending completion of the inspection.

J&J said it would cooperate with Emergent and FDA to address any issues following the inspection, Reuters reports.